MENTAL RETARDE HASTALARDA ANTİKONVÜLSAN KULLANIMININ ROKURONYUM’UN NÖROMUSKÜLER BLOK ÖZELLİKLERİ ÜZERİNE ETKİSİ

Öz

Bu çalışmada mental retarde hastalarda kronik antikonvülsan tedavinin rokuronyumun nöromusküler blok süresine etkisi geriye dönük olarak değerlendirilmiştir. Genel anestezi altında diş tedavisi yapılan ASA I-II 44 mental retarde hastanın verileri retrospektif olarak değerlendirildi. Kronik 3 aydan fazla antikonvülsan ilaç kullanan hastalar Grup 1, ilaç kullanmayan hastalar Grup 2 olarak adlandırıldı. Nöromusküler ileti monitorizasyonu TOF-Guard cihazı Organon Teknika, Denmark ile yapılmıştı. Anestezi indüksiyonu 2-2,5 mg/kg propofol, 0,6 mg/kg rokuronyum, 1µg/kg remifentanil ile sağlanmıştı. Anestezi idamesi %50 N2O/O2 karışımında %2 sevofluran konsantrasyonu ile sağlanmıştı. Hasta kayıtlarından rokuronyumun etki başlangıç süresi EBS , klinik etki süresi KES , derlenme indeksi Dİ ve TOF oranının % 75 T75 , %90 T90 derlenmesine dek geçen süreler kaydedildi. Hastaların demografik verilerinde istatistiksel anlamlı fark yoktu. EBS her iki grupta benzer bulundu Grup 1:104.27±11.15 sn, Grup 2: 103.45±10.92 sn . KES, Dİ ve TOF oranının % 75 T75 , %90 T90 derlenmesine dek geçen süreler Grup 1’ de istatistiksel anlamlı olarak daha kısa bulundu p

Anahtar Kelimeler

• Nöromusküler blok,antikonvülsan tedavi,rokuronyum

EFFECT OF ANTICONVULSANT USE ON THE NEUROMUSCULAR BLOCKING PROPERTIES OF ROCURONIUM IN MENTALLY RETARDED PATIENTS

Abstract

In this study, we retrospectively evaluated the effect of chronic anticonvulsant use on the neuromuscular blocking time of rocuronium in mentally retarded patients. The data of 44 mentally retarded patients of ASA I-II whose dental treatments were carried out under general anaesthesia have been evaluated retrospectively. The patients who used chronic more than 3 months anticonvulsant drugs were named as Group 1 and those who did not use them as Group 2. The neuromuscular transmission was monitored using the TOF-Guard device Organon Teknika, Denmark . The anaesthetic induction was enabled with propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg and remifentanil 1µg/kg. Anaesthesia was maintained with 2% sevoflurane + 50% N2O/O2inhalation. Rocuronium’s onset of action OA , duration of clinical action DCA , recovery index RI and the times elapsed until the TOF ratio recovered by 75% T75 and 90% T90 were recorded from patient records. There was no statistically significant difference in the demographic data of the patients. OA was similar in both groups Group 1: 104.27±11.15 sec. and Group 2: 103.45±10.92 sec. . DCA, RI and the times elapsed until the TOF ratio recovered by 75% T75 and 90% were shorter in Group 1, which was statistically significant p

Keywords

• Muscle relaxants,anticonvulsant,rocuronium

Kaynakça

1. ) Naguib M. Pharmacology of muscle relaxant neuromuscular pharmacology. Anaesthesia. Churchil Livingston, 2006: 481-572. and ed. In: RD, th ed. Philadelphia
2. ) Alloul K, Whalley DG, Shutway, et al. Pharmacokinetic azepine-induced vecuronium neuromuscular blockade in anesthetized patients. Anesthesiology ; 84: 330–9. origin of carbam resistance to ) Hickey DR, Sangwan S, Bevan JC. Phenytoin-induced pancuronium. Anesthesia 1988; 43: –9. resistance to
3. ) Kim MH, Hwang JW, Jeon YT, Do SH. Effects of valproic acid and magnesium sulphate on rocuronium requirement in patients undergoing craniotomy for surgery. Br J ) Matthews T, Weston N, Baxter H, Felce D, Kerr M. A general practice- based prevalence study of epilepsy among adults with intellectual disabilities and of its association with psychiatric disorder, behaviour disturbance and carer Res 2008 ; 52 : 163– 73. Intellect Disabil
4. ) Nunn JH, Davidson G, Gordon PH, Storrs J. A retrospective review of a service to provide comprehensive dental care under general anesthesia. Spec Care Dentist 1995;15 :97- 101. ) S, Fuchs-Buder propofol without muscle relaxants or with different doses of rocuronium for tracheal anaesthesia. Scand. 2000 ;44:720-6. F, Soltész T. Remifentanil and intubation in outpatient Acta Anaesthesiol
5. ) Beydoun A, D'Souza J. Treatment of idiopathic a review of the evidence. Expert Opin Pharmacother 2012 ;13:1283-98.
6. ) McGrother CW, Bhaumik S, Thorp CF, Hauk A, Branford D, WatsonJM. Epilepsy in disabilities:prevalence, associations and service :376–86. with intellectual implications. Seizure ; ) JA, Martínez-Lage Rocuronium-Induced Blockade Phenytoin Neurosurgical :79-82. J, Tortosa JF, Pérez-Ayala M. Neuromuscular Is Affected by Journal Therapy. of Anesthesiology ; ) Spacek A, Neiger FX, Krenn CG, Hoerauf induced neuromuscular block is affected by Anesthesiology 1999; 90: 109–112. therapy.
7. ) Koenig HM, Edwards TL. Cis- atracurium-induced blockade neurosurgical Anesthesiol 2000; 12:314–8. treated J Neurosurg
8. ) Gray HSJ, Slater RM, Pollard BJ. The effect of acutely administered phenytoin on vecuronium-induced neuromuscular blockade. Anesthesia 1989; 44:379–81. ) DC, Boudreault P, Moumdjian R,et al.

9. Cisatracurium-induced blockade is affected by chronic phenytoin or neurosurgical Analg 2005 ;100:538-44. F, Girard D, Chouinard neuromuscular carbamazepine treatment in patients. Anesth mental retardation receiving
10. ) Liberman BA, Norman P, Hardy BG. Pancuronium-phenytoin interaction: A case neuromuscular blockade. Int J Clin Pharmacol Ther Toxicol 1988; 26:371–4.
11. ) Hickey DR, Sangwan S, Bevan JC. Phenytoin-induced pancuronium: Use of atracurium infusion in management of a neurosurgical patient. Anesthesia 1988; 43:757–9. to